Cross-border M&A, deal structuring, due diligence, and corporate finance strategies for mid-market and enterprise transactions.
QXO’s $17 billion acquisition of TopBuild and a wave of cross-border deals in biopharma and manufacturing signal accelerating consolidation across key sectors in 2025. Decision-makers must align financial discipline, regulatory intelligence, and post-merger integration readiness to compete in this environment.
April 2026 has seen a surge in cross-border M&A activity, with UCB’s acquisition of Neurona Therapeutics and Badger Meter’s $100M UDlive deal signalling a structural shift in how European and US strategic acquirers are deploying capital. Decision-makers must now treat due diligence rigour and post-merger integration planning as core competitive capabilities.
Five M&A transactions announced in a single week — led by UCB’s acquisition of Neurona Therapeutics and Badger Meter’s $100M UK deal — reveal accelerating cross-border consolidation across biopharma, industrials, and health tech in Q2 2026. Decision-makers must navigate expanding regulatory obligations and due diligence complexity to protect deal value.
The opening weeks of Q2 2025 reveal a concentrated M&A wave spanning take-privates, AI-driven acquisitions, and $1.45 billion cross-border industrial deals. CFOs, General Counsel, and M&A Directors must recalibrate due diligence and integration frameworks to match the pace and complexity of this new deal environment.
The week of April 16, 2026 has produced a concentrated surge of M&A activity — from Sazerac’s $15 billion bid for Brown-Forman to a $9.4 billion Canadian REIT take-private — signalling structural shifts in how scale, ownership, and technology capability are being valued. For CFOs, General Counsel, and M&A Directors, the patterns demand strategic attention and proactive deal readiness.
Hexagon’s $1.45 billion acquisition of Baker Hughes’ Waygate division headlines a week of concentrated M&A activity spanning industrial technology, luxury hospitality, and specialty finance. Cross-border deal complexity and AI governance are emerging as the defining due diligence challenges of 2026.
Hexagon’s $1.45 billion acquisition of Baker Hughes’ Waygate division headlines a week of M&A activity defined by AI-driven deal rationale and industrial sector consolidation. CFOs and M&A Directors should take note of the due diligence and regulatory implications shaping cross-border transactions in 2026.
From SunOpta’s early HSR clearance to the $8.6B Pinnacle-Synovus all-stock merger, mid-market M&A is accelerating across sectors in 2025. Decision-makers must prioritise regulatory preparation, integration planning, and deal structure discipline to capture value in this fast-moving environment.
From Refresco’s HSR early termination to Wasabi’s cloud acquisition and Oak Hill’s Metronet exit, this week’s M&A deals reveal how regulatory speed, integration strategy, and private credit are reshaping cross-border transactions. Decision-makers should treat antitrust readiness and financing structure as strategic — not administrative — priorities.
April 2026 M&A activity — led by TELCOR’s healthcare AI acquisition and Zone & Co’s procurement deal — reveals a structural shift toward AI-driven consolidation in the mid-market. European decision-makers should treat these North American transactions as a 12-to-18-month leading indicator for their own sectors.